| mRNA | messenger Ribo-Nucleic Acid |
|---|---|
| H-mRNA | H-chain messenger ribonucleic acid |
| mRNA | messenger ribonucleic acid |
| pre-mRNA | precursor messenger ribonucleic acid |
| pre-mRNA | Precursor mRNA |
|---|---|
| mRNA | E-messenger RNA |
| AS | Antisense |
| S | Antisense |
| As-ODN | Antisense oligodeoxynucleotide |
| antisense | <molecular biology> In general the complementary strand of a coding sequence of DNA (antisense DNA) or of mRNA (antisense RNA). A collection of nucleotide sequences which are not templates for synthesis but yet interact with complementary sequences in other molecules thereby causing function of those molecules to be affected. Antisense RNA hybridises with and inactivates mRNA. (12 Dec 1998) |
|---|---|
| antisense DNA | <molecular biology> A synthetic DNA strand that is complementary to a particular strand of target DNA with a complementary sequence of bases. This results in preventing expression of the gene encoded. These proteins can be used to selectively turn off production of certain proteins or block viral genetic instructions, by marking them for destruction by cellular enzymes, in order to prevent the building of new virus or the infection of new cells. (14 Nov 1997) |
| antisense RNA | <molecular biology> A complementary RNA sequence that binds to (and thus blocks the transcription of) a naturally-occuring (sense) messenger RNA molecule. These proteins can be used to selectively turn off production of certain proteins or block viral genetic instructions, by marking them for destruction by cellular enzymes, in order to prevent the building of new virus or the infection of new cells. (09 Oct 1997) |
| antisense strand | <molecular biology> The strand of DNA which is not used during transcription to make mRNA (anticoding strand). The mRNA made during transcription thus has the same sequence as this strand, so that the eventual protein will be a sense version. (13 Jan 1998) |
| antisense therapy | Use of antisense DNA for the inhibition of translation of a specific gene product for therapeutic purposes. (05 Mar 2000) |
| RNA, antisense | An RNA molecule which, by binding to a complementary sequence in either RNA or DNA, inhibits the function and/or completion of synthesis of the latter molecule. It is involved in various regulatory systems in vivo. Artificial antisense rnas have been used to inhibit translation of specific mRNA molecules both in living cells (eukaryotic and bacterial) and in cell-free systems. (12 Dec 1998) |
| DNA, antisense | A DNA molecule which is complementary to the sense strand (that which functions as a template for the synthesis of mRNA) but is not involved in transcription. Both strands are involved in replication. (12 Dec 1998) |
| oligonucleotides, antisense | Short fragments (usually between 2 and 12 nucleotides) of DNA or RNA that are used to hinder or block the translation or processing of mRNA. (12 Dec 1998) |
| alternative mRNA splicing | Splicing different exons in or out of messenger RNA to form different mRNA transcripts. (09 Oct 1997) |
| capping of mRNA | The process of adding a guanosine nucleotide to the 5'-end (the beginning) of an eukaryotic mRNA, then methylating (adding a -CH3 to) the guanosine. (09 Oct 1997) |
| maternal mRNA | <molecular biology> Messenger RNA found in oocytes and early embryos that is derived from the maternal genome during oogenesis. See: masked messenger RNA. (18 Nov 1997) |
| mRNA | <molecular biology> Single stranded RNA molecule that specifies the amino acid sequence of one or more polypeptide chains. This information is translated during protein synthesis when ribosomes bind to the mRNA. In prokaryotes, mRNA is normally formed by splicing a large primary transcript from a DNA sequence and protein synthesis starts while the mRNA is still being synthesised. Prokaryote mRNAs are usually very short lived (average t 1/2 is 5mins.). In contrast, in eukaryotes the primary transcripts (HnRNA) are synthesised in the nucleus and they are extensively processed to give the mRNA that is exported to the cytoplasm where protein synthesis takes place. This processing includes the addition of a 5' 5' linked 7 methyl guanylate cap at the 5' end and a sequence of adenylate groups at the 3' end, the poly A tail, as well as the removal of any introns and the splicing together of exons, only 10% of HnRNA leaves the nucleus. Eukaryote mRNAs are comparatively long lived with a half life ranging from 30minutes to 24 hours. (27 Jun 1999) |
| mRNA (2'-O-methyladenosine-N6-)-methyltransferase | <enzyme> Involved in capping mRNA Registry number: EC 2.1.1.62 Synonym: mRNA n(6)-adenosine methyltransferase, mra methyltransferase, RNA(2'-o-methyladenosine-n(6)-)methyltransferase (26 Jun 1999) |
| mRNA(adenine-N6)-methyltransferase | <enzyme> Methylates mRNA at internal adenosine within the consensus sequence puac(a/c/u) Registry number: EC 2.1.1.- Synonym: mRNA-a-n6-methyltransferase, mRNA(adenine-n6)-methylase (26 Jun 1999) |
| mRNA (guanine(N7))-methyltransferase | <enzyme> Catalyses s-adenosyl-l-methionine and g(5')pppr-RNA to yield s-adenosyl-l-homocysteine and m(7)g(5')pppr-RNA; mRNA containing an n(7)-methylguanine cap Registry number: EC 2.1.1.56 Synonym: mRNA (guanine-7-)methyltransferase, mRNA(guanine-7-)methyltransferase, RNA (guanine-7) methyltransferase, abd1 gene product (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|